全文获取类型
收费全文 | 17232篇 |
免费 | 1148篇 |
国内免费 | 257篇 |
专业分类
耳鼻咽喉 | 110篇 |
儿科学 | 253篇 |
妇产科学 | 192篇 |
基础医学 | 1501篇 |
口腔科学 | 122篇 |
临床医学 | 2352篇 |
内科学 | 3026篇 |
皮肤病学 | 110篇 |
神经病学 | 2786篇 |
特种医学 | 682篇 |
外国民族医学 | 3篇 |
外科学 | 1165篇 |
综合类 | 1874篇 |
一般理论 | 2篇 |
预防医学 | 867篇 |
眼科学 | 112篇 |
药学 | 1158篇 |
9篇 | |
中国医学 | 186篇 |
肿瘤学 | 2127篇 |
出版年
2023年 | 205篇 |
2022年 | 356篇 |
2021年 | 582篇 |
2020年 | 604篇 |
2019年 | 511篇 |
2018年 | 577篇 |
2017年 | 576篇 |
2016年 | 552篇 |
2015年 | 579篇 |
2014年 | 1088篇 |
2013年 | 1296篇 |
2012年 | 877篇 |
2011年 | 1056篇 |
2010年 | 799篇 |
2009年 | 883篇 |
2008年 | 887篇 |
2007年 | 838篇 |
2006年 | 786篇 |
2005年 | 620篇 |
2004年 | 558篇 |
2003年 | 505篇 |
2002年 | 365篇 |
2001年 | 389篇 |
2000年 | 294篇 |
1999年 | 315篇 |
1998年 | 233篇 |
1997年 | 235篇 |
1996年 | 227篇 |
1995年 | 203篇 |
1994年 | 181篇 |
1993年 | 130篇 |
1992年 | 139篇 |
1991年 | 120篇 |
1990年 | 113篇 |
1989年 | 86篇 |
1988年 | 98篇 |
1987年 | 81篇 |
1986年 | 64篇 |
1985年 | 105篇 |
1984年 | 96篇 |
1983年 | 62篇 |
1982年 | 77篇 |
1981年 | 50篇 |
1980年 | 43篇 |
1979年 | 45篇 |
1978年 | 28篇 |
1977年 | 32篇 |
1976年 | 26篇 |
1975年 | 14篇 |
1973年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
2.
3.
目的 观察张氏头针治疗儿童多发性抽动症的临床疗效。方法 2019年3月至2020年12月共招募多发性抽动症儿童60例,随机分为头针组和硫必利组,每组各30例。头针组采用毫针针刺双侧运动区、舞蹈震颤控制区及百会、印堂,每周治疗3次,1个月为1个疗程,共治疗4个疗程;硫必利组给予盐酸硫必利片50-100 mg/次,2次/天,1个月为1个疗程,共治疗4个疗程。比较两组患者治疗前后耶鲁综合抽动严重程度量表(Yale global Tic severity scale,YGTSS)、中医证候积分、SF-36健康调查简表(the MOS item short from health survey,SF-36)及临床疗效评价结果。结果 头针组合硫必利组组内比较:二组的YGTSS评分、中医证候积分与治疗前相比具有显著统计学差异(P<0.05),SF-36评分中头针组在生理功能、生理职能、总体健康、情感职能、心理健康等5个维度的评分高于治疗前,差异有统计学意义(P<0.05);硫必利组在生理功能、生理职能、总体健康、心理健康等5个维度的评分高于治疗前,差异有统计学意义(P<0.05);头针组合硫必利组组间比较:头针组治疗后YGTSS评分、中医证候积分均低于硫必利组,差异有统计学意义(P<0.05),头针组在SF-36量表中总体健康和心理健康2个维度照优于硫必利组,差异有统计学意义(P<0.05);治疗结束3个月随访,头针组YGTSS评分、中医证候积分均低于硫必利组,差异有统计学意义(P<0.05)。结论 张氏头针能够很好的改善多发性抽动症的临床症状,提高其生活质量。 相似文献
4.
《Drug discovery today》2022,27(4):1196-1203
Immuno-positron emission tomography (immunoPET) imaging is a paradigm-shifting imaging technique for whole-body and all-lesion tumor detection, based on the combined specificity of tumor-targeting vectors [e.g., monoclonal antibodies (mAbs), nanobodies, and bispecific antibodies] and the sensitivity of PET imaging. By noninvasively, comprehensively, and serially revealing heterogeneous tumor antigen expression, immunoPET imaging is gradually improving the theranostic prospects for hematological malignancies. In this review, we summarize the available literature regarding immunoPET in imaging hematological malignancies. We also highlight the pros and cons of current conjugation strategies, and modular chemistry that can be leveraged to develop novel immunoPET probes for hematological malignancies. Lastly, we discuss the use of immunoPET imaging in guiding antibody drug development. 相似文献
5.
6.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
7.
《Disability and health journal》2022,15(4):101344
BackgroundThere is increasing research interest regarding physical activity behavior among persons with multiple sclerosis (MS), yet there is little known about physical activity and its correlates in Black persons with MS.ObjectiveThis cross-sectional study assessed associations among social cognitive theory (SCT) variables and device-measured and self-reported physical activity in samples of Black and White persons with MS.MethodsParticipants included 67 Black and 141 White persons with MS who wore an ActiGraph accelerometer on a belt around the waist measuring moderate-to-vigorous physical activity (MVPA) for seven days and completed a battery of questionnaires. Questionnaires included demographic and clinical characteristics, leisure-time exercise, exercise self-efficacy, overcoming barriers self-efficacy, function, social support, exercise outcome expectations, and goal setting and planning.ResultsBlack participants with MS engaged in significantly less MVPA, but not sedentary behavior or light physical activity, than the White participants with MS. Black participants further had significantly lower levels of exercise self-efficacy and outcome expectations than the White sample. All SCT correlates were significantly correlated with self-reported physical activity, but only exercise and barriers self-efficacy, perceived function, and exercise goal setting were associated with device-measured MVPA. The difference in physical activity between Black and White participants with MS was accounted for by differences in exercise self-efficacy and outcome expectations.ConclusionsResearchers should consider developing behavioral interventions that target exercise self-efficacy and outcome expectations as SCT variables for increasing physical activity in Black persons with MS. 相似文献
8.
Paul G. Richardson Fredrik Schjesvold Katja Weisel Philippe Moreau Larry D. Anderson Darrell White Paula Rodriguez-Otero Pieter Sonneveld Monika Engelhardt Matthew Jenner Alessandro Corso Jan Dürig Michel Pavic Morten Salomo Meral Beksac Albert Oriol Jindriska Lindsay Anna Marina Liberati Monica Galli Pawel Robak Alessandra Larocca Munci Yagci Filiz Vural Abraham S. Kanate Ruiyun Jiang Lara Grote Teresa Peluso Meletios Dimopoulos 《European journal of haematology》2022,108(1):73-83
9.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(5):305-311
BackgroundMonoclonal gammopathy of undetermined significance (MGUS) is an indolent, premalignant plasma cell disorder with the potential of transforming into symptomatic multiple myeloma (MM). There are multiple risk factors that contribute to transformation. Agent Orange (AO) has been linked with multiple malignant and nonmalignant conditions.Patients and MethodsWe conducted a retrospective chart review of patients with monoclonal gammopathy who were seen at John D. Dingell Veterans Affairs Medical Center (Detroit, Michigan) between 2005 and 2015 with MGUS, smoldering multiple myeloma, and MM. We explored baseline patient characteristics and explored AO exposure. Dates of diagnosis, dates of progression, and expiration dates were recorded to time to progression and overall survival (OS).ResultsWe identified 211 patients with monoclonal gammopathy; 96% were male and 122 were African American. Eleven patients had reported AO exposure. Cumulative risk of progression in the overall population was 1.4% at 1 year. Risk of transformation in the population exposed to AO was significantly higher with a hazard ratio (HR) of 11.19 (95% confidence interval [CI], 2.10-59.47; P = .005). OS was numerically shorter in AO-exposed patients with a median OS of 7 years compared with 11.1 years in those not exposed. However, AO exposure was not associated with OS in multivariable analysis (HR, 0.50; 95% CI, 0.07-3.83; P = .508).ConclusionMonoclonal gammopathy is a premalignant condition with the risk of progressing to MM. Exposure to AO has been implicated in multiple conditions including MM. Our study demonstrates an increased risk of progression in exposed patients. 相似文献
10.